source · application/json
source_695b3bef78694782
sha256 647ee8855f074f2250ad0486141120b832b246b98e74fd2b425ab746abbae55f
by researka:v2 · 2026-06-24 18:37:06.027775+04:00
{"publication_id": "ea8f0afd-dc89-418d-b158-6e496c6cfe3b", "traces": [{"candidate_sources": [{"doi": "10.1161/circulationaha.122.060511", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "url": "https://doi.org/10.1161/circulationaha.122.060511"}, {"doi": "10.1038/s41591-022-01971-4", "study": "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER", "url": "https://doi.org/10.1038/s41591-022-01971-4"}, {"doi": "10.1161/circulationaha.120.050391", "study": "Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction", "url": "https://doi.org/10.1161/circulationaha.120.050391"}, {"doi": "10.1002/ejhf.1978", "study": "Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF", "url": "https://doi.org/10.1002/ejhf.1978"}, {"doi": "10.1038/s42255-023-00943-3", "study": "Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology", "url": "https://doi.org/10.1038/s42255-023-00943-3"}], "claim": "Across retrieved fact-level receipts for dapagliflozin, which endpoints show directionally favorable versus null/non-convergent signals, and what matched PICO remains untested?", "claim_id": "claim_1"}, {"candidate_sources": [{"doi": "10.1161/circulationaha.122.060511", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "url": "https://doi.org/10.1161/circulationaha.122.060511"}, {"doi": "10.1038/s41591-022-01971-4", "study": "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER", "url": "https://doi.org/10.1038/s41591-022-01971-4"}, {"doi": "10.1161/circulationaha.120.050391", "study": "Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction", "url": "https://doi.org/10.1161/circulationaha.120.050391"}, {"doi": "10.1002/ejhf.1978", "study": "Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF", "url": "https://doi.org/10.1002/ejhf.1978"}, {"doi": "10.1038/s42255-023-00943-3", "study": "Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology", "url": "https://doi.org/10.1038/s42255-023-00943-3"}], "claim": "Finding: Dapagliflozin reduced the risk of death from cardiovascular causes (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76-0.97; P = 0.01)", "claim_id": "claim_2"}, {"candidate_sources": [{"doi": "10.1161/circulationaha.122.060511", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "url": "https://doi.org/10.1161/circulationaha.122.060511"}, {"doi": "10.1038/s41591-022-01971-4", "study": "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER", "url": "https://doi.org/10.1038/s41591-022-01971-4"}, {"doi": "10.1161/circulationaha.120.050391", "study": "Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction", "url": "https://doi.org/10.1161/circulationaha.120.050391"}, {"doi": "10.1002/ejhf.1978", "study": "Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF", "url": "https://doi.org/10.1002/ejhf.1978"}, {"doi": "10.1038/s42255-023-00943-3", "study": "Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology", "url": "https://doi.org/10.1038/s42255-023-00943-3"}], "claim": "This receipt-backed scoping note has one bounded signal: dapagliflozin shows context-dependent, not uniformly convergent associations across this 5-source primary/review bundle (2020-2024). Grouped by direction, directionally favorable: 3 receipt(s) | comparator/not favorable: 1 receipt(s) | economic/context only: 1 receipt(s). The source facts cover 5 population context(s) and 3 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. The listed effect sizes remain source-specific across endpoints and populations; they are not pooled or averaged. Concrete source-level examples: hazard ratio, 0.74 [95% CI, 0.58–0.92]; Dapagliflozin reduced the risk of death from cardiovascular causes (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76-0.97; P = 0.01); The hazard ratio (95% CI) for the primary end point in patients with chronic kidney disease was 0.71 (0.59–0.86).", "claim_id": "claim_3"}, {"candidate_sources": [{"doi": "10.1161/circulationaha.122.060511", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "url": "https://doi.org/10.1161/circulationaha.122.060511"}, {"doi": "10.1038/s41591-022-01971-4", "study": "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER", "url": "https://doi.org/10.1038/s41591-022-01971-4"}, {"doi": "10.1161/circulationaha.120.050391", "study": "Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction", "url": "https://doi.org/10.1161/circulationaha.120.050391"}, {"doi": "10.1002/ejhf.1978", "study": "Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF", "url": "https://doi.org/10.1002/ejhf.1978"}, {"doi": "10.1038/s42255-023-00943-3", "study": "Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology", "url": "https://doi.org/10.1038/s42255-023-00943-3"}], "claim": "null/non-convergent or other/mixed: the extracted fact is null, mixed, or not directionally interpretable.", "claim_id": "claim_4"}, {"candidate_sources": [{"doi": "10.1161/circulationaha.122.060511", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "url": "https://doi.org/10.1161/circulationaha.122.060511"}, {"doi": "10.1038/s41591-022-01971-4", "study": "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER", "url": "https://doi.org/10.1038/s41591-022-01971-4"}, {"doi": "10.1161/circulationaha.120.050391", "study": "Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction", "url": "https://doi.org/10.1161/circulationaha.120.050391"}, {"doi": "10.1002/ejhf.1978", "study": "Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF", "url": "https://doi.org/10.1002/ejhf.1978"}, {"doi": "10.1038/s42255-023-00943-3", "study": "Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology", "url": "https://doi.org/10.1038/s42255-023-00943-3"}], "claim": "directionally favorable: Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER — Dapagliflozin reduced the risk of death from cardiovascular causes (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76-0.97; P = 0.01)", "claim_id": "claim_5"}, {"candidate_sources": [{"doi": "10.1161/circulationaha.122.060511", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "url": "https://doi.org/10.1161/circulationaha.122.060511"}, {"doi": "10.1038/s41591-022-01971-4", "study": "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER", "url": "https://doi.org/10.1038/s41591-022-01971-4"}, {"doi": "10.1161/circulationaha.120.050391", "study": "Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction", "url": "https://doi.org/10.1161/circulationaha.120.050391"}, {"doi": "10.1002/ejhf.1978", "study": "Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF", "url": "https://doi.org/10.1002/ejhf.1978"}, {"doi": "10.1038/s42255-023-00943-3", "study": "Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology", "url": "https://doi.org/10.1038/s42255-023-00943-3"}], "claim": "Specific moderators in this bundle are population/indication (iron-deficient patients with heart failure; patients with heart failure; patients with heart failure with reduced ejection fraction; patients with heart failure with reduced ejection fraction and chronic kidney disease (eGFR <60 mL/min/1.73m²); patients with type 2 diabetes with features of SIDD or SIRD), study design/evidence type (primary/review). Single primary-study estimates are separated from pooled review or meta-analytic estimates rather than treated as interchangeable.", "claim_id": "claim_6"}, {"candidate_sources": [{"doi": "10.1161/circulationaha.122.060511", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "url": "https://doi.org/10.1161/circulationaha.122.060511"}, {"doi": "10.1038/s41591-022-01971-4", "study": "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER", "url": "https://doi.org/10.1038/s41591-022-01971-4"}, {"doi": "10.1161/circulationaha.120.050391", "study": "Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction", "url": "https://doi.org/10.1161/circulationaha.120.050391"}, {"doi": "10.1002/ejhf.1978", "study": "Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF", "url": "https://doi.org/10.1002/ejhf.1978"}, {"doi": "10.1038/s42255-023-00943-3", "study": "Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology", "url": "https://doi.org/10.1038/s42255-023-00943-3"}], "claim": "The selected receipts group because each carries a fact-level extraction for dapagliflozin; they separate by context (human clinical/observational) and endpoint, so they are not interchangeable evidence for one pooled claim.", "claim_id": "claim_7"}, {"candidate_sources": [{"doi": "10.1161/circulationaha.122.060511", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "url": "https://doi.org/10.1161/circulationaha.122.060511"}, {"doi": "10.1038/s41591-022-01971-4", "study": "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER", "url": "https://doi.org/10.1038/s41591-022-01971-4"}, {"doi": "10.1161/circulationaha.120.050391", "study": "Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction", "url": "https://doi.org/10.1161/circulationaha.120.050391"}, {"doi": "10.1002/ejhf.1978", "study": "Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF", "url": "https://doi.org/10.1002/ejhf.1978"}, {"doi": "10.1038/s42255-023-00943-3", "study": "Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology", "url": "https://doi.org/10.1038/s42255-023-00943-3"}], "claim": "The signal is purely descriptive of effect-direction heterogeneity; it cannot support even a weak causal or comparative-efficacy inference, and pooling across these PICOs would be inappropriate.", "claim_id": "claim_8"}]}
metadata
{
"researka_object_type": "publication_sidecar",
"researka_publication_id": "ea8f0afd-dc89-418d-b158-6e496c6cfe3b",
"researka_submission_id": "3af2fac0-d3ac-4f2e-a8dc-bb9295572ad0",
"sidecar_name": "citation_traces.json",
"sidecar_url": "https://api.researka.org/publications/ea8f0afd-dc89-418d-b158-6e496c6cfe3b/sidecars/citation_traces.json"
}